J Neuropathol Exp Neurol 59:314322
The Ghost Trial In the late 1990s and early 2000s, the Croatian pharmaceutical company Pliva sponsored clinical trials for BPC-157 as a treatment for inflammatory bowel disease
Preclinical studies suggest it could have applications in Alzheimers disease, dementia, Parkinsons disease, and traumatic brain injury, while biohackers and peptide researchers are exploring it as a nootropic for memory and learning enhancement
Refrigerate at 36 to 46 degrees Fahrenheit (2 to 8 Celsius) on an interior shelf, not in the door
The injection delivers B1, B6, and B12 directly and is preferred for severe deficiency or malabsorption
Under no circumstances should it be utilised as a drug, agricultural or pesticide product, food additive, or household chemical